Artivion (NYSE:AORT) Announces Earnings Results, Beats Estimates By $0.02 EPS

Artivion (NYSE:AORT) posted its quarterly earnings data on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02, Zacks reports. Artivion had a return on equity of 7.21% and a net margin of 2.55%.The company had revenue of $116.34 million for the quarter, compared to analysts’ expectations of $115.69 million. During the same period in the previous year, the firm posted ($0.01) EPS. Artivion’s revenue was up 17.5% compared to the same quarter last year.

Here are the key takeaways from Artivion’s conference call:

• Artivion exercised its option to acquire Endospan after FDA PMA of the NEXUS aortic arch stent graft, expects close in Q2 2026, funded by a $150M term‑loan draw to pay the $135M upfront, and plans a U.S. commercial launch on January 1, 2027 with NEXUS positioned as a platform supported by three additional PMA programs.
• The company trimmed full‑year 2026 guidance to 7%–11% adjusted constant‑currency revenue growth ($480M–$496M) and now expects adjusted EBITDA of $100M–$107M (or $92M–$99M including an estimated $8M of incremental Endospan‑related expenses), citing softer stent graft sales and timing of AMDS starter set orders.
• AMDS implant and reorder rates outperformed expectations, but initial “starter set” sales lag because hospitals face a ~$100k upfront stocking cost and some are deferring until anticipated mid‑2026 PMA/IRB simplification; management expects set sales to accelerate after PMA and via programs to ease the upfront burden.
• Q1 performance showed operational leverage: total revenue +12% (constant currency), adjusted EBITDA +26% to $22.1M with a 19% margin (≈130 bps improvement), improved gross margin (64.9%), better free cash flow versus prior year, and net leverage reduced to 1.8x from 4.0x.

Artivion Stock Down 28.4%

NYSE AORT traded down $10.06 on Friday, hitting $25.36. 5,135,733 shares of the stock were exchanged, compared to its average volume of 340,683. Artivion has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a 50-day moving average price of $36.50 and a 200-day moving average price of $41.19. The company has a market cap of $1.23 billion, a PE ratio of 105.69 and a beta of 1.41. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Artivion reported Q1 2026 revenue of $116.3 million, up 18% year over year, and adjusted EPS of $0.08, topping analyst estimates. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Adjusted EBITDA rose 26% to $22.1 million, showing improving profitability as the company grows. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: The FDA approved the NEXUS Aortic Arch System, a meaningful regulatory win that could expand Artivion’s addressable market and support future growth. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Artivion exercised its option to acquire Endospan, which may strengthen its aortic disease portfolio over time. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Neutral Sentiment: The company guided 2026 revenue to $480 million-$496 million, which is near Wall Street expectations but not a major upside surprise. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Negative Sentiment: Despite the beat-and-raise style quarter, investors appear focused on the stock’s rich valuation and the lack of a major guidance surprise, contributing to the selloff. Why is Artivion stock plummeting today?
• Negative Sentiment: Citizens JMP and Needham both lowered price targets, which may have added to the negative sentiment even though both firms kept bullish ratings. Benzinga report on lowered price targets

Insider Activity at Artivion

In related news, SVP Marshall S. Stanton sold 2,149 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $81,189.22. Following the transaction, the senior vice president directly owned 60,097 shares of the company’s stock, valued at $2,270,464.66. This trade represents a 3.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Amy Horton sold 901 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company’s stock, valued at approximately $5,254,744.64. This trade represents a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 133,043 shares of company stock worth $4,977,158 over the last three months. Company insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the 3rd quarter valued at about $27,000. Smartleaf Asset Management LLC lifted its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Artivion in the fourth quarter valued at about $79,000. Quadrant Capital Group LLC purchased a new stake in shares of Artivion during the 3rd quarter worth approximately $92,000. Finally, iSAM Funds UK Ltd purchased a new stake in Artivion during the third quarter worth $131,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Canaccord Genuity Group dropped their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Stifel Nicolaus set a $55.00 target price on Artivion in a research note on Thursday, March 5th. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Friday, April 10th. Finally, Needham & Company LLC decreased their price target on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.